前沿生物(688221) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was CNY 28,328,182.53, representing a 14.93% increase compared to CNY 24,648,130.00 in the same period last year[3]. - Total operating revenue for Q1 2025 was CNY 28,328,182.53, an increase of 14.3% compared to CNY 24,648,130.00 in Q1 2024[14]. - The net profit attributable to shareholders was a loss of CNY 44,121,517.41, an improvement from a loss of CNY 55,706,177.98 year-over-year[3]. - Net loss for Q1 2025 was CNY 44,121,517.41, an improvement from a net loss of CNY 55,706,177.98 in Q1 2024, representing a 20.5% reduction in losses[15]. - The company reported a total comprehensive loss of CNY 44,099,957.95 for Q1 2025, an improvement from CNY 55,705,964.26 in Q1 2024[15]. Research and Development - R&D expenses totaled CNY 16,803,233.38, a significant decrease of 50.68% from CNY 34,071,674.17 in the previous year, with R&D investment accounting for 59.32% of revenue, down 78.91 percentage points[3]. - Research and development expenses significantly decreased to CNY 16,803,233.38 from CNY 34,071,674.17, a decline of 50.7%[14]. Cash Flow and Assets - The net cash flow from operating activities was -CNY 48,669,328.08, compared to -CNY 43,749,418.44 in the previous year[3]. - Cash flow from operating activities showed a net outflow of CNY 48,669,328.08, compared to a net outflow of CNY 43,749,418.44 in the same period last year[16]. - The company's total current assets decreased from CNY 1,222.62 million as of December 31, 2024, to CNY 1,130.07 million as of March 31, 2025[11]. - The company's cash and cash equivalents decreased from CNY 248.98 million to CNY 221.97 million during the same period[11]. - Cash and cash equivalents at the end of Q1 2025 were CNY 218,010,949.55, down from CNY 526,400,496.91 at the beginning of the period[18]. - The company's total assets at the end of the reporting period were CNY 1,723,742,799.34, a decrease of 4.88% from CNY 1,812,138,179.73 at the end of the previous year[4]. - The company's total assets decreased from CNY 1,812.14 million to CNY 1,723.74 million during the same period[12]. - The company's total liabilities decreased from CNY 670.83 million to CNY 626.53 million from December 31, 2024, to March 31, 2025[13]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 11,392[7]. - The largest shareholder, Jianmu Pharmaceutical Co., Ltd., holds 70,638,750 shares, representing 18.86% of the total shares[8]. Operational Highlights - The company has seen a significant increase in accounts payable, which rose by 96.80%, indicating increased operational activity[5]. - In Q1 2025, the company achieved revenue of CNY 28.33 million, a year-on-year increase of 14.93%, primarily driven by the sales growth of its core product, Aikening®[9]. - The company has focused on three outpatient groups: high viral load patients, those with suboptimal antiviral treatment, and patients with incomplete immune reconstitution, enhancing clinical application in outpatient settings to boost sales[9]. - As of March 2025, the company has successfully introduced the antiviral drug Veklury® in 29 provinces across the country, generating stable revenue[10]. - The company continues to advance its diversified business strategy, focusing on enhancing the clinical promotion of Aikening® in both inpatient and outpatient settings[9]. Investment Activities - Investment activities generated a net cash inflow of CNY 62,384,367.43, contrasting with a net cash outflow of CNY 307,550,372.78 in Q1 2024[17]. Earnings and Returns - The weighted average return on equity was -3.94%, an improvement from -4.24% in the same period last year[3]. - Basic and diluted earnings per share improved to CNY -0.12 from CNY -0.15 year-over-year[15]. - The company's net loss increased from CNY 1.96 billion to CNY 2.00 billion in retained earnings[13]. Operating Costs - Total operating costs decreased to CNY 74,909,155.77 from CNY 86,698,546.20, a reduction of 13.6% year-over-year[14].